Is Ebglyss Approved for Atopic Dermatitis?
Yes, Ebglyss (lebrikizumab-lbkz) is FDA-approved for moderate-to-severe atopic dermatitis (AD) in adults and children 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Eli Lilly received approval in September 2024.[1]
How Does Ebglyss Work for AD?
Ebglyss is an interleukin-13 (IL-13) inhibitor that targets a key protein driving skin inflammation in AD. Patients inject it subcutaneously every two weeks after initial doses, reducing itch and rash.[1]
Who Can Use Ebglyss and When?
It's for patients 12+ with body weight at least 40 kg who need systemic therapy. Not for mild cases controlled by topicals. Prescribers monitor for hypersensitivity reactions like eye inflammation.[1]
How Does Ebglyss Compare to Dupixent?
Both are biologics for AD, but Ebglyss blocks only IL-13 while Dupixent (dupilumab) blocks IL-4 and IL-13. Trials showed Ebglyss clears skin in 33-43% of patients at 16 weeks versus 13-21% on placebo; Dupixent hits similar rates but requires weekly dosing initially. No head-to-head data exists.[1][2]
Common Side Effects Patients Report
Herpes infections (3-5%), eye inflammation (1-2%), and injection site reactions occur most often. Serious risks include hypersensitivity—stop if severe. Long-term data is emerging post-approval.[1]
Cost and Access for AD Treatment
List price is about $8,500 per month before discounts. Commercial insurance often covers it with prior authorization; patient assistance programs exist via Lilly. Biosimilars unlikely soon due to new patents.[3]
Patent Status and Generic Timeline
Key U.S. patents on Ebglyss expire in 2038-2040, per DrugPatentWatch.com. No Paragraph IV challenges filed yet, delaying generics.[4]
[1]: FDA Approval Letter for Ebglyss (Sep 2024), fda.gov
[2]: ADHERE Trials (NEJM 2023), nejm.org
[3]: Lilly Pricing Info, lilly.com
[4]: DrugPatentWatch.com, drugpatentwatch.com